Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report.

Tamer YazarHülya Olgun YazarMurat Cihan

Published in: Acta neurologica Belgica (2020)

In conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
cognitive decline
patient reported outcomes
current status
bioinformatics analysis